ClinicalTrials.gg
CompletedNCT02964247Updated Nov 17, 2020Results posted

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 82 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-17.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
34th of 151
303 · median 62
Started
2017
with 5 others
Phase 3
45 of 151
1 open now
Registered
125th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 34th largest by enrollment, is one of 6 that started in 2017, is one of 45 in phase 3, and was the 125th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 303 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
  • Male or female, age 18 years or older at the time of signing informed consent.
  • Diagnosed with type 2 diabetes mellitus.
  • of 7.0-9.5% (53-80 mmol/mol) (both inclusive).
  • Stable dose of an SGLT-2 inhibitor as monotherapy or in combination (including fixed-dose drug combination) with a stable dose of metformin (1500 mg or more, or maximum tolerated dose) for at least 90 days prior to the day of screening. All medications in compliance with current local label.
  • of 20 kg/m\^2 or above.

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method (adequate contraceptive measure as required by local regulation or practice).
  • History of diabetic ketoacidosis while being treated with SGLT2 inhibitors.
  • Renal impairment measured as estimated (eGFR) value of less than 60 mL/min/1.73m\^2 as defined by Kidney Disease Improving Global Outcomes (KDIGO) classification using isotope dilution mass spectrometry (IDMS) for serum creatinine measured at screening.
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days during the 90 days prior to screening is allowed.
  • Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Family is defined as a first degree relative.
  • History or presence of pancreatitis (acute or chronic).
  • Impaired liver function, defined as 2.5 or more times upper normal limit at screening.
  • Subjects presently classified as being in (NYHA) Class IV.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
303 participants (actual)

Study arms

  • Experimental
    liraglutide + SGLT2i ± metformin

    Drug: liraglutide

  • Placebo comparator
    liraglutide placebo + SGLT2i ± metformin

    Drug: placebo

Interventions

  • Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks

  • Drugplacebo

    Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks

07

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change from baseline (week 0) to week 26 in glycosylated haemoglobin was evaluated for 2 different observation period 'in-trial' observation period and 'on-treatment without rescue medication" observation period. The 'in-trial' observation period represents the time-period where subjects were considered to be in the trial, regardless of whether or not the subjects had initiated rescue medication or prematurely discontinued trial product. The 'on-treatment' observation period is the part of the in-trial observation period during which subjects were treated with the trial product, that is the time from the first dose to the last dose of trial product. The 'on-treatment without rescue medication' observation period is a part of 'on-treatment' observation period during which subjects were considered treated with trial product and had not initiated any rescue medications.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Change in Body Weight

    Change from baseline (week 0) to week 26 in body weight was evaluated for 2 different observation period 'in-trial' observation period and 'on-treatment without rescue medication" observation period. The 'in-trial' observation period represents the time-period where subjects were considered to be in the trial, regardless of whether or not the subjects had initiated rescue medication or prematurely discontinued trial product. The 'on-treatment' observation period is the part of the in-trial observation period during which subjects were treated with the trial product, that is the time from the first dose to the last dose of trial product. The 'on-treatment without rescue medication' observation period is a part of 'on-treatment' observation period during which subjects were considered treated with trial product and had not initiated any rescue medications.

    Time frame: Week 0, Week 26

  2. Change in Fasting Plasma Glucose

    Change from baseline (week 0) to week 26 in fasting plasma glucose ('in-trial' observation period)

    Time frame: Week 0, Week 26

  3. Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol), American Diabetes Association Target

    Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol), American Diabetes Association target, after 26 weeks ('in-trial' observation period)

    Time frame: Week 26

  4. Subjects Who Achieve HbA1c Below or Equal to 6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists Target

    Percentage of subjects who achieve HbA1c below or equal to 6.5% (48 mmol/mol), American Association of Clinical Endocrinologists target, after 26 weeks ('in-trial' observation period)

    Time frame: Week 26

  5. Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) Without Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes and no Weight Gain.

    Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol) without severe or blood glucose confirmed symptomatic hypoglycaemia episodes and no weight gain, after 26 weeks ('in-trial' observation period)

    Time frame: Week 26

  6. Subjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol) and Weight Loss Above or Equal to 3%.

    Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and weight loss above or equal to 3%, after 26 weeks ('in-trial' observation period)

    Time frame: Week 26

  7. Change in Self-measured Plasma Glucose 7-point Profile - Mean 7-point Profile

    Change in self-measured plasma glucose 7-point profile - mean 7-point profile after 26 weeks. Subjects were instructed to measure their plasma glucose at following 7 timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime. Mean of the 7-point profile was calculated ('in-trial' observation period).

    Time frame: Week 0, Week 26

  8. Change in Self-measured Plasma Glucose 7-point Profile - Mean Post Prandial Increments (Over All Meals)

    Subjects were instructed to measure their plasma glucose at following 7 timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime. The mean increment over all meals was derived as the mean of all available meal increments ('in-trial' observation period)

    Time frame: Week 0, Week 26

  9. Change in Body Mass Index (BMI)

    Observed mean change from baseline (week 0) to week 26 in body mass index (BMI). BMI was calculated based on body weight and height ('in-trial' observation period)

    Time frame: Week 0, Week 26

  10. Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) and no Weight Gain

    Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol) and no weight gain, after 26 week ('in-trial' observation period).

    Time frame: Week 26

  11. Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol), no Weight Gain and Systolic Blood Pressure Below 140 mmHg.

    Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol), no weight gain and systolic blood pressure below 140 mmHg, after 26 weeks ('in-trial' observation period)

    Time frame: Week 26

  12. Subjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol)

    Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol), after 26 weeks ('in-trial' observation period)

    Time frame: Week 26

  13. Subjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol) and no Weight Gain

    Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and no weight gain, after 26 weeks.

    Time frame: Week 26

  14. Number of Treatment Emergent Adverse Events

    The on-treatment summary of adverse events includes treatment-emergent events with onset on or after the first day of exposure to randomised treatment and no later than the minimum of the date of the follow-up visit or the last day of randomised treatment + 7 days or the date of last subject-investigator contact.

    Time frame: Week 0 - 26 + 7 days

  15. Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes

    Treatment emergent hypoglycaemic episode is defined episode with onset on or after the first day of exposure to randomised treatment and no later than the minimum of the date of the follow-up visit or the last day of randomised treatment + 1 days or the date of last subject-investigator contact. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to American Diabetes Association's (ADA) classification or blood glucose confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions.

    Time frame: Week 0 - 26

  16. Change in Fasting Blood Lipids - Total Cholesterol

    Fasting total cholesterol measured in mg/dL. Observed mean change in fasting total cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.

    Time frame: Week 0, Week 26

  17. Change in Fasting Blood Lipids - Low Density Lipoprotein (LDL) Cholesterol

    Low density lipoprotein (LDL) cholesterol measured in mg/dL. Observed mean change in fasting low density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.

    Time frame: Week 0, Week 26

  18. Change in Fasting Blood Lipids - High Density Lipoprotein (HDL) Cholesterol

    High density lipoprotein (HDL) cholesterol measured in mg/dL. Observed mean change in fasting high density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.

    Time frame: Week 0, Week 26

  19. Change in Fasting Blood Lipids - Very Low Density Lipoprotein (VLDL) Cholesterol

    Very low density lipoprotein (VLDL) cholesterol measured in mg/dL. Observed mean change in fasting very low density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.

    Time frame: Week 0, Week 26

  20. Change in Fasting Blood Lipids-triglycerides

    Fasting triglycerides measured in mg/dL. Observed mean change in fasting triglycerides from baseline (week 0) to week 26 is presented as ratio to baseline value.

    Time frame: Week 0, Week 26

  21. Change in Fasting Blood Lipids- Free Fatty Acids (FFA)

    Free fatty acids measured in mg/dL. Observed mean change in fasting free fatty acids from baseline (week 0) to week 26 is presented as ratio to baseline value.

    Time frame: Week 0, Week 26

  22. Change in Waist Circumference

    Change from baseline (week 0) to week 26 in waist circumference ('in-trial' observation period).

    Time frame: Week 0, Week 26

  23. Change in Systolic Blood Pressure

    Change from baseline (week 0) in systolic blood pressure after 26 weeks ('in-trial' observation period).

    Time frame: Week 0, Week 26

  24. Change in Diastolic Blood Pressure

    Change from baseline (week 0) in diastolic blood pressure after 26 weeks ('in-trial' observation period).

    Time frame: Week 0, Week 26

  25. Subjects Who Achieve Weight Loss by 3% or More

    Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and weight loss above or equal to 3%, after 26 weeks ('in-trial' observation period).

    Time frame: Week 26

08

Results

Posted Jul 10, 2019

Participant flow

The trial was conducted at 74 sites in 7 countries. All the sites have screened and randomised subjects. Brazil: 3 sites, India: 7 sites, Israel: 6 sites, Mexico: 2 sites, Russian Federation: 3 sites, United Arab Emirates: 5 sites, United States: 48 sites screened and randomised subjects.

Participant flow — Overall Study
MilestoneLiraglutidePlacebo
Started203100
Exposed to trial product202100
Completed20098
Not completed32
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryChange in HbA1c

Change from baseline (week 0) to week 26 in glycosylated haemoglobin was evaluated for 2 different observation period 'in-trial' observation period and 'on-treatment without rescue medication" observation period. The 'in-trial' observation period represents the time-period where subjects were considered to be in the trial, regardless of whether or not the subjects had initiated rescue medication or prematurely discontinued trial product. The 'on-treatment' observation period is the part of the in-trial observation period during which subjects were treated with the trial product, that is the time from the first dose to the last dose of trial product. The 'on-treatment without rescue medication' observation period is a part of 'on-treatment' observation period during which subjects were considered treated with trial product and had not initiated any rescue medications.

Time frame:
Week 0, Week 26
Reported as:
Mean · Percentage of HbA1c
Change in HbA1c
Percentage of HbA1cLiraglutidePlacebo
in-trial obs. period-1.00 ± 0.86-0.32 ± 0.83
on-treatment without rescue medication obs. period-1.05 ± 0.85-0.35 ± 0.80
Statistical analysis
  • Liraglutide vs Placebo · pattern mixture model · p = <.001 · Treatment difference: -0.68 · 95% CI -0.89 to -0.48Liraglutide - Placebo
  • Liraglutide vs Placebo · Mixed Models Analysis · p = <.001 · Treatment difference: -0.74 · 95% CI -0.94 to -0.53Liraglutide - Placebo
SecondaryChange in Body Weight

Change from baseline (week 0) to week 26 in body weight was evaluated for 2 different observation period 'in-trial' observation period and 'on-treatment without rescue medication" observation period. The 'in-trial' observation period represents the time-period where subjects were considered to be in the trial, regardless of whether or not the subjects had initiated rescue medication or prematurely discontinued trial product. The 'on-treatment' observation period is the part of the in-trial observation period during which subjects were treated with the trial product, that is the time from the first dose to the last dose of trial product. The 'on-treatment without rescue medication' observation period is a part of 'on-treatment' observation period during which subjects were considered treated with trial product and had not initiated any rescue medications.

Time frame:
Week 0, Week 26
Reported as:
Mean · Kg
Change in Body Weight
KgLiraglutidePlacebo
in-trial obs. period-2.84 ± 3.83-2.02 ± 3.32
on-treatment without rescue medication obs. period-2.89 ± 3.81-2.09 ± 2.96
Statistical analysis
  • Liraglutide vs Placebo · pattern mixture model · p = 0.077 · Treatment difference: -0.82 · 95% CI -1.73 to 0.09Liraglutide - Placebo
  • Liraglutide vs Placebo · Mixed Models Analysis · p = 0.062 · Treatment difference: -0.86 · 95% CI -1.77 to 0.04Liraglutide - Placebo
SecondaryChange in Fasting Plasma Glucose

Change from baseline (week 0) to week 26 in fasting plasma glucose ('in-trial' observation period)

Time frame:
Week 0, Week 26
Reported as:
Mean · milligram/dL
Change in Fasting Plasma Glucose
milligram/dLLiraglutidePlacebo
Change in Fasting Plasma Glucose-27.00 ± 35.01-11.97 ± 45.20
SecondarySubjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol), American Diabetes Association Target

Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol), American Diabetes Association target, after 26 weeks ('in-trial' observation period)

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol), American Diabetes Association Target
Percentage of ParticipantsLiraglutidePlacebo
Yes51.7923.16
No48.2176.84
SecondarySubjects Who Achieve HbA1c Below or Equal to 6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists Target

Percentage of subjects who achieve HbA1c below or equal to 6.5% (48 mmol/mol), American Association of Clinical Endocrinologists target, after 26 weeks ('in-trial' observation period)

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Subjects Who Achieve HbA1c Below or Equal to 6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists Target
Percentage of ParticipantsLiraglutidePlacebo
Yes34.369.47
No65.6490.53
SecondarySubjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) Without Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes and no Weight Gain.

Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol) without severe or blood glucose confirmed symptomatic hypoglycaemia episodes and no weight gain, after 26 weeks ('in-trial' observation period)

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) Without Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes and no Weight Gain.
Percentage of ParticipantsLiraglutidePlacebo
Yes47.6919.15
No52.3180.85
SecondarySubjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol) and Weight Loss Above or Equal to 3%.

Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and weight loss above or equal to 3%, after 26 weeks ('in-trial' observation period)

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Subjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol) and Weight Loss Above or Equal to 3%.
Percentage of ParticipantsLiraglutidePlacebo
Yes29.747.45
No70.2692.55
SecondaryChange in Self-measured Plasma Glucose 7-point Profile - Mean 7-point Profile

Change in self-measured plasma glucose 7-point profile - mean 7-point profile after 26 weeks. Subjects were instructed to measure their plasma glucose at following 7 timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime. Mean of the 7-point profile was calculated ('in-trial' observation period).

Time frame:
Week 0, Week 26
Reported as:
Mean · milligram/dL
Change in Self-measured Plasma Glucose 7-point Profile - Mean 7-point Profile
milligram/dLLiraglutidePlacebo
Change in Self-measured Plasma Glucose 7-point Profile - Mean 7-point Profile-33.93 ± 37.17-18.85 ± 40.81
SecondaryChange in Self-measured Plasma Glucose 7-point Profile - Mean Post Prandial Increments (Over All Meals)

Subjects were instructed to measure their plasma glucose at following 7 timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime. The mean increment over all meals was derived as the mean of all available meal increments ('in-trial' observation period)

Time frame:
Week 0, Week 26
Reported as:
Mean · milligram/dL
Change in Self-measured Plasma Glucose 7-point Profile - Mean Post Prandial Increments (Over All Meals)
milligram/dLLiraglutidePlacebo
Change in Self-measured Plasma Glucose 7-point Profile - Mean Post Prandial Increments (Over All Meals)-11.06 ± 41.29-4.44 ± 44.77
SecondaryChange in Body Mass Index (BMI)

Observed mean change from baseline (week 0) to week 26 in body mass index (BMI). BMI was calculated based on body weight and height ('in-trial' observation period)

Time frame:
Week 0, Week 26
Reported as:
Mean · kg/m^2
Change in Body Mass Index (BMI)
kg/m^2LiraglutidePlacebo
Change in Body Mass Index (BMI)-1.02 ± 1.40-0.72 ± 1.20
SecondarySubjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) and no Weight Gain

Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol) and no weight gain, after 26 week ('in-trial' observation period).

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol) and no Weight Gain
Percentage of ParticipantsLiraglutidePlacebo
Yes47.6919.15
No52.3180.85
SecondarySubjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol), no Weight Gain and Systolic Blood Pressure Below 140 mmHg.

Percentage of subjects who achieve HbA1c below 7.0% (53 mmol/mol), no weight gain and systolic blood pressure below 140 mmHg, after 26 weeks ('in-trial' observation period)

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Subjects Who Achieve HbA1c Below 7.0% (53 mmol/Mol), no Weight Gain and Systolic Blood Pressure Below 140 mmHg.
Percentage of ParticipantsLiraglutidePlacebo
Yes42.0518.09
No57.9581.91
SecondarySubjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol)

Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol), after 26 weeks ('in-trial' observation period)

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Subjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol)
Percentage of ParticipantsLiraglutidePlacebo
Yes52.3116.84
No47.6983.16
SecondarySubjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol) and no Weight Gain

Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and no weight gain, after 26 weeks.

Time frame:
Week 26
Reported as:
Number · Percentage of Participants
Subjects Who Achieve HbA1c Reduction Above or Equal to 1% (11mmol/Mol) and no Weight Gain
Percentage of ParticipantsLiraglutidePlacebo
Yes45.1314.89
No54.8785.11
SecondaryNumber of Treatment Emergent Adverse Events

The on-treatment summary of adverse events includes treatment-emergent events with onset on or after the first day of exposure to randomised treatment and no later than the minimum of the date of the follow-up visit or the last day of randomised treatment + 7 days or the date of last subject-investigator contact.

Time frame:
Week 0 - 26 + 7 days
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events
EventsLiraglutidePlacebo
Number of Treatment Emergent Adverse Events426106
SecondaryNumber of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes

Treatment emergent hypoglycaemic episode is defined episode with onset on or after the first day of exposure to randomised treatment and no later than the minimum of the date of the follow-up visit or the last day of randomised treatment + 1 days or the date of last subject-investigator contact. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to American Diabetes Association's (ADA) classification or blood glucose confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions.

Time frame:
Week 0 - 26
Reported as:
Number · Episodes
Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes
EpisodesLiraglutidePlacebo
Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemia Episodes03
SecondaryChange in Fasting Blood Lipids - Total Cholesterol

Fasting total cholesterol measured in mg/dL. Observed mean change in fasting total cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.

Time frame:
Week 0, Week 26
Reported as:
Geometric mean · Ratio
Change in Fasting Blood Lipids - Total Cholesterol
RatioLiraglutidePlacebo
Change in Fasting Blood Lipids - Total Cholesterol0.95 ± 45.10.99 ± 42.3
SecondaryChange in Fasting Blood Lipids - Low Density Lipoprotein (LDL) Cholesterol

Low density lipoprotein (LDL) cholesterol measured in mg/dL. Observed mean change in fasting low density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.

Time frame:
Week 0, Week 26
Reported as:
Geometric mean · Ratio
Change in Fasting Blood Lipids - Low Density Lipoprotein (LDL) Cholesterol
RatioLiraglutidePlacebo
Change in Fasting Blood Lipids - Low Density Lipoprotein (LDL) Cholesterol0.97 ± 58.61.01 ± 54.1
SecondaryChange in Fasting Blood Lipids - High Density Lipoprotein (HDL) Cholesterol

High density lipoprotein (HDL) cholesterol measured in mg/dL. Observed mean change in fasting high density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.

Time frame:
Week 0, Week 26
Reported as:
Geometric mean · Ratio
Change in Fasting Blood Lipids - High Density Lipoprotein (HDL) Cholesterol
RatioLiraglutidePlacebo
Change in Fasting Blood Lipids - High Density Lipoprotein (HDL) Cholesterol1.05 ± 41.41.01 ± 39.7
SecondaryChange in Fasting Blood Lipids - Very Low Density Lipoprotein (VLDL) Cholesterol

Very low density lipoprotein (VLDL) cholesterol measured in mg/dL. Observed mean change in fasting very low density lipoprotein cholesterol from baseline (week 0) to week 26 is presented as ratio to baseline value.

Time frame:
Week 0, Week 26
Reported as:
Geometric mean · Ratio
Change in Fasting Blood Lipids - Very Low Density Lipoprotein (VLDL) Cholesterol
RatioLiraglutidePlacebo
Change in Fasting Blood Lipids - Very Low Density Lipoprotein (VLDL) Cholesterol0.83 ± 69.00.94 ± 64.5
SecondaryChange in Fasting Blood Lipids-triglycerides

Fasting triglycerides measured in mg/dL. Observed mean change in fasting triglycerides from baseline (week 0) to week 26 is presented as ratio to baseline value.

Time frame:
Week 0, Week 26
Reported as:
Geometric mean · Ratio
Change in Fasting Blood Lipids-triglycerides
RatioLiraglutidePlacebo
Change in Fasting Blood Lipids-triglycerides0.81 ± 71.50.93 ± 70.0
SecondaryChange in Fasting Blood Lipids- Free Fatty Acids (FFA)

Free fatty acids measured in mg/dL. Observed mean change in fasting free fatty acids from baseline (week 0) to week 26 is presented as ratio to baseline value.

Time frame:
Week 0, Week 26
Reported as:
Geometric mean · Ratio
Change in Fasting Blood Lipids- Free Fatty Acids (FFA)
RatioLiraglutidePlacebo
Change in Fasting Blood Lipids- Free Fatty Acids (FFA)0.80 ± 86.60.86 ± 92.0
SecondaryChange in Waist Circumference

Change from baseline (week 0) to week 26 in waist circumference ('in-trial' observation period).

Time frame:
Week 0, Week 26
Reported as:
Mean · cm
Change in Waist Circumference
cmLiraglutidePlacebo
Change in Waist Circumference-4.28 ± 11.19-1.77 ± 4.42
SecondaryChange in Systolic Blood Pressure

Change from baseline (week 0) in systolic blood pressure after 26 weeks ('in-trial' observation period).

Time frame:
Week 0, Week 26
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure
mmHgLiraglutidePlacebo
Change in Systolic Blood Pressure-1.95 ± 13.42-3.35 ± 12.36
SecondaryChange in Diastolic Blood Pressure

Change from baseline (week 0) in diastolic blood pressure after 26 weeks ('in-trial' observation period).

Time frame:
Week 0, Week 26
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure
mmHgLiraglutidePlacebo
Change in Diastolic Blood Pressure-0.72 ± 8.04-1.12 ± 8.55
SecondarySubjects Who Achieve Weight Loss by 3% or More

Percentage of subjects who achieve HbA1c reduction above or equal to 1% (11mmol/mol) and weight loss above or equal to 3%, after 26 weeks ('in-trial' observation period).

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Subjects Who Achieve Weight Loss by 3% or More
Percentage of participantsLiraglutidePlacebo
Yes46.4341.24
No53.5758.76

Adverse events

Collected over Week 0 (randomisation visit) to week 26 (end-of-treatment visit) + 7 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide0/202 (0%)5/202 (2.5%)87/202 (43.1%)
Placebo0/100 (0%)1/100 (1%)8/100 (8%)
Most frequent serious events
Most frequent serious events
EventLiraglutidePlacebo
Acute kidney injuryRenal and urinary disorders0/2021/100
UreterolithiasisRenal and urinary disorders0/2021/100
Angina unstableCardiac disorders1/2020/100
Cardiac failure congestiveCardiac disorders1/2020/100
CholecystitisHepatobiliary disorders1/2020/100
Congestive cardiomyopathyCardiac disorders1/2020/100
Eyelid cystEye disorders1/2020/100
HaemorrhoidsGastrointestinal disorders1/2020/100
Lower gastrointestinal haemorrhageGastrointestinal disorders1/2020/100
Most frequent other events
Most frequent other events
EventLiraglutidePlacebo
NauseaGastrointestinal disorders53/2026/100
Decreased appetiteMetabolism and nutrition disorders19/2020/100
DiarrhoeaGastrointestinal disorders19/2023/100
ConstipationGastrointestinal disorders18/2020/100
VomitingGastrointestinal disorders17/2022/100

Baseline characteristics

Full analysis set (FAS) includes all randomised subjects. Subjects in the FAS contribute to the evaluation 'as randomised'.

Age, Continuous
Age, Continuous(Years)LiraglutidePlaceboTotal
Mean54.72 ± 10.0856.03 ± 9.8955.15 ± 10.02
Sex: Female, Male
Sex: Female, Male(Participants)LiraglutidePlaceboTotal
Female7842120
Male12558183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LiraglutidePlaceboTotal
Hispanic or Latino593594
Not Hispanic or Latino14465209
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LiraglutidePlaceboTotal
American Indian or Alaska Native011
Asian381553
Native Hawaiian or Other Pacific Islander101
Black or African American12517
White13159190
Other212041
09

Study locations

82 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35294, United States
  • Novo Nordisk Investigational Site
    Montgomery, Alabama 36109, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85741, United States
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    Sacramento, California 95821, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Vista, California 92083, United States
  • Novo Nordisk Investigational Site
    Gainesville, Florida 32653, United States
  • Novo Nordisk Investigational Site
    Hollywood, Florida 33024, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32216, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32256, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32258, United States
  • Novo Nordisk Investigational Site
    Maitland, Florida 32751, United States
  • Novo Nordisk Investigational Site
    Miami Lakes, Florida 33016, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33165, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33176, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33606, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, Georgia 30046, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Statesboro, Georgia 30461, United States
  • Novo Nordisk Investigational Site
    Blackfoot, Idaho 83221, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47714, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    New Orleans, Louisiana 70115, United States
  • Novo Nordisk Investigational Site
    Kalamazoo, Michigan 49009, United States
  • Novo Nordisk Investigational Site
    Rochester, Michigan 48307, United States
  • Novo Nordisk Investigational Site
    Billings, Montana 59101, United States
  • Novo Nordisk Investigational Site
    Henderson, Nevada 89052-2649, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12203, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28210, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28226, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28277, United States
  • Novo Nordisk Investigational Site
    Kinston, North Carolina 28501, United States
  • Novo Nordisk Investigational Site
    Wilmington, North Carolina 28401, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45245, United States
  • Novo Nordisk Investigational Site
    Columbus, Ohio 43212, United States
  • Novo Nordisk Investigational Site
    McMurray, Pennsylvania 15317, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15243, United States
  • Novo Nordisk Investigational Site
    Moncks Corner, South Carolina 29461, United States
  • Novo Nordisk Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • Novo Nordisk Investigational Site
    Myrtle Beach, South Carolina 29572, United States
  • Novo Nordisk Investigational Site
    Spartanburg, South Carolina 29303, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38119, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37203, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Edinburg, Texas 78539, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77024, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030, United States
  • Novo Nordisk Investigational Site
    Humble, Texas 77338, United States
  • Novo Nordisk Investigational Site
    Round Rock, Texas 78681, United States
  • Novo Nordisk Investigational Site
    Schertz, Texas 78154, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99201, United States
  • Novo Nordisk Investigational Site
    Curitiba, Parana 80030-110, Brazil
  • Novo Nordisk Investigational Site
    Porto Alegre, Rio Grande Do Sul 90035-170, Brazil
  • Novo Nordisk Investigational Site
    São Paulo, Sao Paulo 01228-000, Brazil
  • Novo Nordisk Investigational Site
    Ahmedabad, Gujarat 380008, India
  • Novo Nordisk Investigational Site
    Bangalore, Karnataka 560 017, India
  • Novo Nordisk Investigational Site
    Indore, Madhya Pradesh 452010, India
  • Novo Nordisk Investigational Site
    Pune, Maharashtra 411004, India
  • Novo Nordisk Investigational Site
    Jaipur, Rajasthan 302006, India
  • Novo Nordisk Investigational Site
    Coimbatore, Tamil Nadu 641009, India
  • Novo Nordisk Investigational Site
    Hyderabad, Telengana 500003, India
  • Novo Nordisk Investigational Site
    Kolkata, West Bengal 700080, India
  • Novo Nordisk Investigational Site
    New Delhi, 110001, India
  • Novo Nordisk Investigational Site
    Haifa, 35152, Israel
  • Novo Nordisk Investigational Site
    Kfar Saba, 44281, Israel
  • Novo Nordisk Investigational Site
    Tel Hashomer, 52621, Israel
  • Novo Nordisk Investigational Site
    Tel-Aviv, 62038, Israel
  • Novo Nordisk Investigational Site
    Ponce, 00716, Puerto Rico
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 190013, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 190068, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 195197, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 199226, Russian Federation
  • Novo Nordisk Investigational Site
    St. Petersburg, 194354, Russian Federation
  • Novo Nordisk Investigational Site
    Al Ain, 1006, United Arab Emirates
  • Novo Nordisk Investigational Site
    Dubai, 7272, United Arab Emirates
  • Novo Nordisk Investigational Site
    Umm Al Quwain, 24, United Arab Emirates
  • Novo Nordisk Investigational Site
    Umm Al Quwain, 499, United Arab Emirates
10

References and documents

Publications

  • Blonde L, Belousova L, Fainberg U, Garcia-Hernandez PA, Jain SM, Kaltoft MS, Mosenzon O, Nafach J, Palle MS, Rea R. Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2020 Jun;22(6):929-937. doi: 10.1111/dom.13978. Epub 2020 Feb 14. PubMed 31984646 ↗
  • Blonde L, Fainberg U, Kaltoft MS, Mosenzon O, Ramesh C, Rea R. Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i. Diabetes Obes Metab. 2021 Oct;23(10):2234-2241. doi: 10.1111/dom.14464. Epub 2021 Jul 8. PubMed 34132018 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in May 2018, 14 months.

Results were first posted in Jul 2019, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 14 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2016
First posted
Nov 16, 2016
StartActual
Mar 3, 2017
Primary completionActual
May 4, 2018
CompletionActual
May 8, 2018
Results first posted
Jul 10, 2019
Last update
Nov 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02964247
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 16, 2016
Start date
Mar 3, 2017
Primary completion
May 4, 2018
Completion
May 8, 2018
Results posted
Jul 10, 2019
Last update
Nov 17, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion